Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

To compare irinotecan (CPT-11)+gemcitabine vs CPT-11 alone as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) progressing after docetaxel–cisplatinum-based therapy. A total of 147 evaluable, pretreated patients, with NSCLC, received either gemcitabine (1000 mg m(−...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgoulias, V, Kouroussis, C, Agelidou, A, Boukovinas, I, Palamidas, P, Stavrinidis, E, Polyzos, A, Syrigos, K, Veslemes, M, Toubis, M, Ardavanis, A, Tselepatiotis, E, Vlachonikolis, I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409833/
https://www.ncbi.nlm.nih.gov/pubmed/15238986
http://dx.doi.org/10.1038/sj.bjc.6602010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409833/
https://www.ncbi.nlm.nih.gov/pubmed/15238986
http://dx.doi.org/10.1038/sj.bjc.6602010

Ejemplares similares